Literature DB >> 16936331

Circulating levels of Nepsilon-(carboxymethyl)lysine are increased in systemic sclerosis.

O Kaloudi1, G Basta, F Perfetto, F Bartoli, A Del Rosso, I Miniati, M L Conforti, S Generini, S Guiducci, R Abbate, A Pignone, S Castellani, R Livi, R De Caterina, M Matucci-Cerinic.   

Abstract

OBJECTIVE: Advanced glycation endproducts (AGEs), including Nepsilon-(carboxymethyl)lysine-protein adducts (CML) are involved in micro/macrovascular changes and are co-localized with adhesion molecules in inflamed tissues. Serum levels of CML were investigated in systemic sclerosis (SSc) characterized by microvascular modifications and correlated with indices of micro/macrovascular damage.
METHODS: In 66 SSc patients (limited SSc, n = 55; diffuse SSc, n = 11) and 20 controls, CML serum levels were measured by enzyme-linked immunosorbent assay. Nailfold capillaroscopy, intima-media thickness (IMT) and the ankle-brachial index (ABI) were also recorded, to characterize micro/macrovascular involvement.
RESULTS: CML levels were significantly higher in SSc (79.2 +/- 39 mg/ml vs 49.6 +/- 26.1 mg/ml, mean +/- s.d.; P<0.01), without significant differences between SSc subsets. CML levels were significantly higher in all capillaroscopic patterns: the 'early' pattern showed higher levels than 'active' and 'late' patterns. IMT was significantly higher in SSc (P<0.01) than in controls, whilst ABI was no different from controls.
CONCLUSIONS: These data indicate that although both CML formation and macrovascular involvement are increased in SSc, there is no correlation between these two parameters. However, the characteristic early nailfold capillaroscopy changes of SSc are associated with proportionally greater CML formation, suggesting that AGEs are involved in SSc microangiopathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16936331     DOI: 10.1093/rheumatology/kel076

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  12 in total

1.  Atherosclerosis in Systemic Sclerosis: a Modern Controversy.

Authors:  Stefania L Magda; Raluca I Mincu; Carmen M Mihai; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Buchar)       Date:  2015-09

Review 2.  A critical view on cardiovascular risk in systemic sclerosis.

Authors:  Antonios Psarras; Stergios Soulaidopoulos; Alexandros Garyfallos; George Kitas; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2016-07-12       Impact factor: 2.631

Review 3.  Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis.

Authors:  Karen Au; Manjit K Singh; Vijay Bodukam; Sangmee Bae; Paul Maranian; Rikke Ogawa; Brennan Spiegel; Maureen McMahon; Bevra Hahn; Dinesh Khanna
Journal:  Arthritis Rheum       Date:  2011-07

4.  Systemic sclerosis is associated with lower limb vascular stiffness and microvascular impairment: results from a prospective study.

Authors:  Charles Cassius; Vannina Seta; Jean-Benoit Monfort; Nathalie Abdoucheli Baudot; Sébastien Rivière; Arsène Mekinian; Camille Frances; Annick Barbaud; Patricia Senet
Journal:  Clin Rheumatol       Date:  2021-03-06       Impact factor: 2.980

Review 5.  Cardiovascular disease in systemic sclerosis.

Authors:  Francesca Cannarile; Valentina Valentini; Giulia Mirabelli; Alessia Alunno; Riccardo Terenzi; Filippo Luccioli; Roberto Gerli; Elena Bartoloni
Journal:  Ann Transl Med       Date:  2015-01

6.  Association between carotid diameter and the advanced glycation end product N-epsilon-carboxymethyllysine (CML).

Authors:  Marcus Baumann; Tom Richart; Daniel Sollinger; Jaroslav Pelisek; Marcel Roos; Tatiana Kouznetsova; Hans-Henning Eckstein; Uwe Heemann; Jan A Staessen
Journal:  Cardiovasc Diabetol       Date:  2009-08-06       Impact factor: 9.951

7.  Deterioration of lung function is associated with presence of IgM rheumatoid factor and smoking in patients with systemic sclerosis.

Authors:  Berit Broholm; Susanne Ullman; Poul Halberg; Søren Jacobsen
Journal:  Clin Rheumatol       Date:  2008-06-05       Impact factor: 2.980

8.  Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic stress, is not increased in patients with systemic sclerosis.

Authors:  M E Hettema; H Bootsma; R Graaff; R de Vries; C G M Kallenberg; A J Smit
Journal:  Int J Rheumatol       Date:  2011-09-29

9.  Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors.

Authors:  Martha E Hettema; Dan Zhang; Karina de Leeuw; Ymkje Stienstra; Andries J Smit; Cees G M Kallenberg; Hendrika Bootsma
Journal:  Arthritis Res Ther       Date:  2008-04-25       Impact factor: 5.156

10.  Ischemic arterial events and atherosclerosis in patients with systemic sclerosis: a population-based case-control study.

Authors:  Annica Nordin; Kerstin Jensen-Urstad; Lena Björnådal; Susanne Pettersson; Anders Larsson; Elisabet Svenungsson
Journal:  Arthritis Res Ther       Date:  2013-08-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.